KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts

被引:90
作者
Ohshimo, S [1 ]
Yokoyama, A [1 ]
Hattori, N [1 ]
Ishikawa, N [1 ]
Hirasawa, Y [1 ]
Kohno, N [1 ]
机构
[1] Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Internal Med, Div Clin Med Sci,Programs Appl Biomed, Hiroshima, Japan
关键词
interstitial lung disease; idiopathic pulmonary fibrosis; therapeutic agent; apoptosis;
D O I
10.1016/j.bbrc.2005.10.144
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The serum level of KL-6, a MUC1 mucin, is a clinically useful marker for various interstitial lung diseases. Previous studies demonstrated that KL-6 promotes chemotaxis of human fibroblasts. However, the pathophysiological role of KL-6 remains poorly understood. Here, we further investigate the functional aspects of KL-6 in proliferation and apoptosis of lung fibroblasts. KL-6 accelerated the proliferation and inhibited the apoptosis of all human lung fibroblasts examined. An anti-KL-6 monoclonal antibody counteracted both of these effects induced by KL-6 on human lung fibroblasts. The pro-fibroproliferative and anti-apoptotic effects of KL-6 are greater than and additive to those of the maximum effective concentrations of platelet-derived growth factor, basic fibroblast growth factor, and transforming growth factor-beta. These findings indicate that increased levels of KL-6 in the epithelial lining fluid may stimulate fibrotic processes in interstitial lung diseases and raise the possibility of applying an anti-KL-6 antibody to treat interstitial lung diseases. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1845 / 1852
页数:8
相关论文
共 35 条
[31]   Resistance to Fas-mediated apoptosis in human lung fibroblast [J].
Tanaka, T ;
Yoshimi, M ;
Maeyama, T ;
Hagimoto, N ;
Kuwano, K ;
Hara, N .
EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (02) :359-368
[32]  
WU SH, 2005, AM J RESP CELL MOL B
[33]   Fibrotic disease and the TH1/TH2 paradigm [J].
Wynn, TA .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (08) :583-594
[34]   Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis [J].
Yokoyama, A ;
Kohno, N ;
Hamada, H ;
Sakatani, M ;
Ueda, E ;
Kondo, K ;
Hirasawa, Y ;
Hiwada, K .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (05) :1680-1684
[35]   Requirement of transforming growth factor-beta (TGF-beta) type II receptor for TGF-beta-induced proliferation and growth [J].
Zhao, Y ;
Young, SL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (05) :2369-2372